Pfizer Announces FDA Has Approved Ruxience (Rituximab-Pvvr) For The Treatment Of Adult Patients With Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, And Granulomatosis With Polyangiiti And Microscopic Polyangiitis